key: cord-0741301-lkzhexwu authors: Ogbuoji, Osondu; Mao, Wenhui; Aryeetey, Genevieve title: The long-term impact of COVID-19 on development assistance for health is still uncertain date: 2021-09-22 journal: Lancet DOI: 10.1016/s0140-6736(21)01448-3 sha: acf52b5c80c1b36d704a04f0bc7443a38e692c20 doc_id: 741301 cord_uid: lkzhexwu nan The COVID-19 pandemic is continuing to have an unprecedented effect on lives, livelihoods, and economies around the world. Some experts speculate that COVID-19 will become endemic, requiring a shift from an emergency response to a long-term sustainable strategy. 1,2 Modelling the impact of COVID-19 on total health expenditure and development assistance for health into the future is therefore challenging while the pandemic is ongoing. In The Lancet, the Global Burden of Disease 2020 Health Financing Collaborator Network estimate the amount of total health expenditure and development assistance for health from 1990 to 2050, 3 using new data sources to update previous estimates from 1990 to 2018. 4, 5 They estimate funding for 2019-20 with a special focus on COVID-19, and forecast health spending for 2021-50. They report that annual development assistance for health reached US$54·4 billion in 2020, of which $13·5 billion was targeted at the COVID-19 response ($12·1 billion in new commitments and $1·4 billion reallocated from other health projects). They also report geographical inequalities in disbursements, finding that some countries with a high COVID-19 burden received less funding than less affected countries. The new Article goes further than previous attempts at quantifying this expenditure by comparing COVID-19-related development assistance for health to non-COVID-19 development assistance for health, preventing double counting of resources by differentiating funding entities from organisations that serve as funding channels, differentiating new funds for COVID-19 from funds reallocated from other health projects towards COVID-19, and using robust statistical methods. These estimates will enhance planning and coordination of COVID-19 response policies. Policy makers and funders will now have clearer visibility of the volume and allocation of funds, enabling them to address financial gaps in the response to the pandemic. For example, countries in Latin America and the Caribbean received only 8% of the COVID-19 development assistance for health despite having 39% of the COVID-19 deaths in 2020. This is a critical gap in funding from an equity and global health perspective. Moreover, funders can see the activity of other funders, allowing them to explore collaborations or fill existing funding gaps. However, as useful as these estimates are for policy making, they should be interpreted with caution. The methods used in the study, though robust, have limitations described elsewhere. 6, 7 The estimates do not fully account for the uncertainties created by COVID-19, or the likelihood of a future COVID-19like pandemic. COVID-19 might trigger a new age of sustained increase in development assistance for health similar to HIV between 2001 and 2010, when development assistance for health increased by 11·2% per year and annual development assistance for health tripled between 2001 and 2010. 5 Conversely, slow economic growth in donor countries coupled with rising nationalism and donor fatigue might lead to decreased development assistance for health. Indeed, the announcement by the UK Government to cut bilateral aid to 102 countries in the middle of the pandemic shows how little is known about donorcountry responses to the pandemic. Furthermore, the models used to estimate future government health expenditure and development assistance for health rely heavily on projections of the gross domestic product (GDP). As a result, the models Lung cancer is the leading cause of cancer-related mortality worldwide. 1 Surgical resection is the mainstay of therapy for patients with stage I-II and select stage IIIA non-small-cell lung cancer (NSCLC). Despite complete surgical excision, patients with NSCLC have high rates of relapse. 2 Historically, strategies to mitigate risk of relapse have focused on adjuvant chemotherapy. In randomised studies, adjuvant chemotherapy improves overall survival, but the degree of benefit is modest, and treatment is associated with clinically significant toxicity. 3 Until recently, progress in developing adjuvant therapies for NSCLC had been largely stagnant, which is in stark contrast with advanced NSCLC, where new therapeutics have been driven by the emergence of two treatment strategies: immune checkpoint inhibitors and targeted therapy. 1 Immune checkpoint inhibitors, targeting PD-1 and its ligand (PD-L1), have since become the cornerstones of first-line therapy for patients with advanced NSCLC with no targetable alterations. With this success, efforts have focused on moving these agents into earlier stages of disease. fail to capture important political shifts created by crises such as pandemics that could influence health spending over and above the impact of the GDP. Several countries increased investments in health relative to the GDP following national crises. China increased investments in universal health coverage after the SARS-CoV outbreak, 8, 9 as did Rwanda after the genocide. 10 Following the Asian financial crisis, Thailand increased spending but Indonesia did not. 11 Lastly, it is not clear that the model sufficiently captured the changing frequency of outbreaks, the differential impact on the economy, and the subsequent effect on development assistance for health. 12, 13 Taken together, these concerns illustrate the potential impact of COVID-19 on future government health expenditure and development assistance for health. The ultimate direction and magnitude of the impact is not certain and will depend on which of the counteracting forces prevail. It is therefore impossible to say exactly how health spending and development assistance for health will change over the next 30 years. Although these projections reflect the current state of knowledge, they might quickly become outdated as situations change and more evidence becomes available. We declare no competing interests. The authors thank Gavin Yamey for feedback on an early version. Immunological characteristics govern the transition of COVID-19 to endemicity Covid-19 will become endemic but with decreased potency over time, scientists believe Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries Institute for Health Metrics and Evaluation. Financing global health 2017: funding universal health coverage and the unfinished HIV/AIDS agenda Tracking aid for global health goals: a systematic comparison of four approaches applied to reproductive, maternal, newborn, and child health Improving tracking of aid for women's, children's, and adolescents' health Universal health coverage: the case of China Lessons and prospects of Universal Health Coverage in China: the importance of equity, quality, and affordability WHO country cooperation strategy: Rwanda 2009-2013. Brazzaville: World Health Organization Regional Office for Africa The impact of the 1997-98 East Asian economic crisis on health and health care in Indonesia Gavi the Vaccine Alliance. 5 reasons why pandemics like COVID-19 are becoming more likely The International Bank for Reconstruction and Development/ The World Bank